Downstream effects of first line bevacizumab (bev) on outcomes after recurrence in advanced ovarian cancer

被引：1
|
作者：
Bishop, E. [1 ]
Perry, L. [1 ]
Previs, R. [2 ]
Alvarez-Secord, A. [2 ]
Moore, K. [1 ]
机构：
[1] Univ Oklahoma, Oklahoma City, OK USA
[2] Duke Univ, Med Ctr, Durham, NC USA
来源：
GYNECOLOGIC ONCOLOGY | 2012年 / 125卷
关键词：
D O I：
10.1016/j.ygyno.2011.12.263
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
262
引用
收藏
页码：S110 / S110
页数：1
相关论文
共 50 条
  • [1] Bevacizumab in the First-line Treatment of advanced Ovarian Cancer
    Mallmann, Michael R.
    Alakus, Hakan
    Mallmann, Peter
    Bruns, Christiane
    [J]. ONKOLOGE, 2019, 25 (11): : 1020 - 1021
  • [2] BEVACIZUMAB- CONTAINING FIRST LINE CHEMOTHERAPY MIGHT REDUCE PROGRESSION-FREE SURVIVAL AFTER RECURRENCE IN ADVANCED EPITHELIAL OVARIAN CANCER
    Perri, T.
    Bart, Y.
    Beiner, M.
    Brandt, B.
    Helpman, L.
    Ben-Baruch, G.
    Korach, J.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1628 - 1628
  • [3] BEVACIZUMAB-CONTAINING FIRST LINE CHEMOTHERAPY MIGHT REDUCE PROGRESSION-FREE SURVIVAL AFTER RECURRENCE IN ADVANCED EPITHELIAL OVARIAN CANCER
    Perri, T.
    Bart, Y.
    Beiner, M.
    Brandt, B.
    Helpman, L.
    Ben-Baruch, G.
    Korach, J.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 523 - 523
  • [4] First-line treatment of women with advanced ovarian cancer: focus on bevacizumab
    Marchetti, Claudia
    Muzii, Ludovico
    Romito, Alessia
    Panici, Pierluigi Benedetti
    [J]. ONCOTARGETS AND THERAPY, 2019, 12 : 1095 - 1103
  • [5] Real-world outcomes of first-line maintenance with niraparib or bevacizumab in advanced ovarian cancer.
    Vasudevan, Anupama
    English, Sandy
    Gart, Mike
    Oladipo, Taofikat
    Hartman, John
    Iadeluca, Laura L.
    Kudrik, Fred J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] Bevacizumab with Chemotherapy as a First-Line Treatment for Advanced Ovarian Cancer in a Serbian Cohort
    Conic, Irena
    Nedovic, Bojan
    Stojnev, Slavica
    Todorovska, Ilinka
    Dimitrijevic, Aleksandra
    Krstic, Miljan
    Djordjevic, Ivana
    Djordjevic, Biljana
    [J]. MEDICINA-LITHUANIA, 2022, 58 (05):
  • [7] Treatment preferences of patients with advanced ovarian cancer for the addition of bevacizumab to first line therapy
    Park, Y.
    Lee, J. Y.
    Nam, E. J.
    Kim, S.
    Kim, S. W.
    Kim, Y. T.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 804 - 804
  • [8] BODY MASS INDEX AND BEVACIZUMAB IN FIRST LINE TREATMENT FOR ADVANCED OVARIAN CANCER (AOC)
    Petrillo, M.
    Paris, I.
    Amadio, G.
    Giovannoni, S.
    Salutari, V.
    Fagotti, A.
    Ricci, C.
    Ferrandina, M. G.
    Distefano, M.
    Scambia, G.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 687 - 687
  • [9] BEVACIZUMAB (BEV) IN FIRST LINE WITH STANDART TREATMENT IN OVARY CANCER IN ADVANCED STAGE, EXPERIMENT OF DEPARTMENT OF MEDICAL ONCOLOGY
    Hadjarab, F.
    Taibi, A.
    Bouzid, K.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 953 - 953
  • [10] Safety of maintenance bevacizumab after first-line chemotherapy for advanced ovarian and mullerian cancers
    Campos, S. M.
    Dizon, D. S.
    Cannistra, S. A.
    Roche, M.
    Krasner, C. N.
    Berlin, S. T.
    Horowitz, N. S.
    DiSilvestro, P.
    Matulonis, U. A.
    Penson, R. T.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345